Lupin’s specialty business is backed by in-depth research and robust manufacturing capabilities. Driven by a steady supply and strong marketing, we have expanded our commercial presence globally with a diverse portfolio across therapy areas such as respiratory, ophthalmology, and CNS.
Our footprint in the specialty segment
With an extensive supply-chain network and deep roots in science, our U.S. specialty business has established a strong presence in the respiratory segment with the addition of asthma and COPD brands, including Xopenex HFA®.
Xopenex HFA is our specialty prescription respiratory drug that acts as a bronchodilator and delivers levalbuterol via an inhaler. This medication supports acute symptom management while helping in long-term respiratory care.
By leveraging scientific capabilities, operational excellence, and strategic partnerships, we continue to strengthen our specialty portfolio across key therapeutic areas while enhancing access and outcomes for patients.
Our Europe business continues to expand in specialty medication across the region. With NaMuscla, Lupin’s flagship specialty neurology therapy, we are addressing the unmet needs of patients who have rare and debilitating neuromuscular disorders. Approved by the European Medicines Agency to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders, the product reflects Lupin’s innovation commitment in areas with limited treatment options.
We are accelerating access to NaMuscla across key European markets, with the help of Lupin Neurosciences, headquartered in Zug, Switzerland.
The business is advancing pediatric development through clinical trials to broaden NaMuscula’s therapeutic potential. We are also conducting new studies to assess NaMuscula's broader capabilities in treating myotonic dystrophy, helping patients regain their mobility.
This sustained investment showcases our focus on improving mobility, functional outcomes, and quality of life for patients in the Muscular segment.
Lupin is expanding its specialty ophthalmology business with the acquisition of VISUfarma from GHO Capital, a pan-European ophthalmic firm with an established portfolio of 60+ branded eye health products.
This strategic expansion increases our presence in key markets, including Italy, the UK, Spain, Germany, and France. It also widens our offerings in areas such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and nutraceuticals tailored for ophthalmologists.
The acquisition supports Lupin’s long-term specialty growth strategy by tapping into the growing global demand for advanced eye care, driven by aging population and rising diabetes-related complications.
Our Canadian subsidiary is expanding its portfolio and broadening its footprint by specializing in gastroenterology and women’s health segments. Majority of our business is driven by our specialty focus, with key products including Zaxine®, Relistor®, and Intrarosa®.
To expand our specialty niche, we recently acquired Nalcrom® from Sanofi and in-licensed three branded products for Attention-Deficit/Hyperactivity Disorder (ADHD).
